Cycloserine Drug Asset Due Diligence Report 2026

This Cycloserine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

175

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Cycloserine can convert its Small molecule drug profile and ddlA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cycloserine (query alias: cycloserine)
Modality / target	Small molecule drug; ddlA; ddlA inhibitors, alr inhibitors
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	McLean Hospital, Inc., Cerovene, Inc., Zhejiang Hisun Pharmaceutical Co., Ltd.

The MCP disease footprint includes Pulmonary Tuberculosis, Bronchopulmonary Dysplasia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07506265	Phase 4	Completed	105	Anesthetic success defined as no response to thermal test, electric pulp test and lip numbness and no pain (VAS ≤ 0 or no subjective pain/stimulation response) during endodontic access and initial instrumentation without need for additional anesthesia
NCT07542548	Phase 4	Completed	1	Frequency of treatment related serious adverse event
NCT07593222	Phase 1/2	Not yet recruiting	100	P30 TMS-Evoked Potential (TEP) Amplitude

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain

Phase 2; n=203; evaluation: not stated. Reported fields: Change in Numeric Rating Scale (NRS) Pain Score 0-10; Higher Worse(Mean) = 4.70 units on a scale (Standard Error, 2.27); -; -

Frequency of serious adverse events on therapy with modified fully oral shorter treatment regimens (mSTR) for MDR/RR-TB

Not Applicable; n=250; evaluation: Positive. Reported fields: SAE = 43.0 Event ( 1.4 - 2.6)

Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain

Phase 4; n=24; evaluation: not stated. Reported fields: Visual Analog Scale (VAS)(Mean) = 3.0 units on a scale (Standard Deviation, 1.5); -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cycloserine addresses Pulmonary Tuberculosis, Bronchopulmonary Dysplasia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2003-01-01	Lilly MDR-TB Partnership	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Adjunctive d-cycloserine augmentation of transcranial magnetic stimulation (TMS) therapy for major depressive disorder”. The milestone feed surfaced a patent-application signal described as “Cycloserine and pentoxifylline combination therapy for treatment of depression”. The milestone feed surfaced a patent-application signal described as “Combination therapy of cycloserine and lithium for the treatment of depression”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO